Calliditas announces final outcome of simplified mandatory offer to the shareholders of Genkyotex December 16, 2020 17:47 CET Non Regulatory Read more
Save the date: Calliditas to host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021 December 9, 2020 13:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report November 11, 2020 11:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial November 9, 2020 10:00 CET Non Regulatory Read more
Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020 October 19, 2020 08:00 CET Non Regulatory Read more
The 200[th] patient’s last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020 October 1, 2020 09:45 CET Non Regulatory Read more
First patient in China enrolled in clinical phase 3 study NefIgArd with lead candidate Nefecon September 8, 2020 08:00 CET Non Regulatory Read more
Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report August 11, 2020 14:00 CET Non Regulatory Read more
CEO Renée Aguiar-Lucander exercises warrants and invests SEK 15.7m (appr. USD 1.7m) in Calliditas June 22, 2020 08:00 CET Non Regulatory Read more
Calliditas provides a corporate business update in the context of the Covid-19 pandemic April 27, 2020 08:00 CET Non Regulatory Read more
Calliditas strengthens its US Commercial Organization April 1, 2020 08:00 CET Non Regulatory Read more
Positive opinion received from EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the treatment of IgAN January 22, 2020 08:00 CET Non Regulatory Read more